Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2018

Open Access 01-12-2018 | Research

Introducing novel and comprehensive models for predicting recurrence in breast cancer using the group LASSO approach: are estimates of early and late recurrence different?

Authors: Majid Akrami, Peyman Arasteh, Tannaz Eghbali, Hadi Raeisi Shahraki, Sedigheh Tahmasebi, Vahid Zangouri, Abbas Rezaianzadeh, Abdolrasoul Talei

Published in: World Journal of Surgical Oncology | Issue 1/2018

Login to get access

Abstract

Background

In here, we constructed personalized models for predicting breast cancer (BC) recurrence according to timing of recurrence (as early and late recurrence).

Methods

An efficient algorithm called group LASSO was used for simultaneous variable selection and risk factor prediction in a logistic regression model.

Results

For recurrence < 5 years, age (OR 0.96, 95% CI = 0.95–0.97), number of pregnancies (OR 0.94, 95% CI = 0.89–0.99), family history of other cancers (OR 0.73, 95% CI = 0.60–0.89), hormone therapy (OR 0.76, 95% CI = 0.61–0.96), dissected lymph nodes (OR 0.98, 95% CI = 0.97–0.99), right-sided BC (OR 0.87, 95% CI = 0.77–0.99), diabetes (OR 0.77, 95% CI = 0.60–0.98), history of breast operations (OR 0.38, 95% CI = 0.17–0.88), smoking (OR 5.72, 95% CI = 2.11–15.55), history of breast disease (OR 3.32, 95% CI = 1.92–5.76), in situ component (OR 1.58, 95% CI = 1.35–1.84), tumor necrosis (OR 1.87, 95% CI = 1.57–2.22), sentinel lymph node biopsy (SLNB) (OR 2.90, 95% CI = 2.05–4.11) and SLNB+axillary node dissection (OR 3.50, 95% CI = 2.26–5.42), grade 3 (OR 1.79, 95% CI = 1.46–2.21), stage 2 (OR 2.71, 95% CI = 2.18–3.35), stages 3 and 4 (OR 5.01, 95% CI = 3.52–7.13), and mastectomy+radiotherapy (OR 2.97, 95% CI = 2.39–3.68) were predictors of recurrence < 5 years. Moreover, relative to mastectomy without radiotherapy (as reference for comparison), quadrantectomy without radiotherapy had a noticeably higher odds ratio compared to quadranectomy with radiotherapy for recurrence < 5 years. (OR 17.58, 95% CI = 6.70–46.10 vs. OR: 2.50, 95% CI = 2–3.12).
Accuracy, sensitivity, and specificity of the model were 82%, 75.6%, and 74.9%, respectively.
For recurrence > 5 years, stage 2 cancer (OR 1.67, 95% CI = 1.31–2.14) and radiotherapy+mastectomy (OR 2.45, 95% CI = 1.81–3.32) were significant predictors; furthermore, relative to mastectomy without radiotherapy (as reference for comparison), quadranectomy without radiotherapy had a noticeably higher odds ratio compared to quadranectomy with radiotherapy for recurrence > 5 years (OR 7.62, 95% CI = 1.52–38.15 vs. OR 1.75, 95% CI = 1.32–2.32). Accuracy, sensitivity, and specificity of the model were 71%, 78.8%, and 55.8%, respectively.

Conclusion

For the first time, we constructed models for estimating recurrence based on timing of recurrence which are among the most applicable models with excellent accuracy (> 80%).
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE Jr, Jeong JH, Tan-Chiu E, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24(13):2028–37.CrossRefPubMed Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE Jr, Jeong JH, Tan-Chiu E, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24(13):2028–37.CrossRefPubMed
3.
go back to reference Zhang Y, Schroeder BE, Jerevall PL, Ly A, Nolan H, Schnabel CA, et al. A novel breast cancer index for prediction of distant recurrence in HR+ early stage breast cancer with 1 to 3 positive nodes. Clin Cancer Res. 2017. Zhang Y, Schroeder BE, Jerevall PL, Ly A, Nolan H, Schnabel CA, et al. A novel breast cancer index for prediction of distant recurrence in HR+ early stage breast cancer with 1 to 3 positive nodes. Clin Cancer Res. 2017.
4.
go back to reference Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010;12(1):R1.CrossRefPubMedPubMedCentral Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010;12(1):R1.CrossRefPubMedPubMedCentral
5.
go back to reference Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer. 2012;107(5):800–7.CrossRefPubMedPubMedCentral Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer. 2012;107(5):800–7.CrossRefPubMedPubMedCentral
6.
go back to reference Kim W, Kim KS, Lee JE, Noh DY, Kim SW, Jung YS, et al. Development of novel breast cancer recurrence prediction model using support vector machine. J Breast Cancer. 2012;15(2):230–8.CrossRefPubMedPubMedCentral Kim W, Kim KS, Lee JE, Noh DY, Kim SW, Jung YS, et al. Development of novel breast cancer recurrence prediction model using support vector machine. J Breast Cancer. 2012;15(2):230–8.CrossRefPubMedPubMedCentral
7.
go back to reference Michaelson JS, Chen LL, Bush D, Fong A, Smith B, Younger J. Improved web-based calculators for predicting breast carcinoma outcomes. Breast Cancer Res Treat. 2011;128(3):827–35.CrossRefPubMed Michaelson JS, Chen LL, Bush D, Fong A, Smith B, Younger J. Improved web-based calculators for predicting breast carcinoma outcomes. Breast Cancer Res Treat. 2011;128(3):827–35.CrossRefPubMed
8.
go back to reference Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Ser B Methodol. 1996;58(1):267–88. Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Ser B Methodol. 1996;58(1):267–88.
9.
go back to reference Wu X, Ye Y, Barcenas CH, Chow WH, Meng QH, Chavez-MacGregor M, Hildebrandt MAT, Zhao H, Gu X, Deng Y, Wagar E, Esteva FJ, Tripathy D, Hortobagyi GN. Personalized prognostic prediction models for breast cancer recurrence and survival incorporating multidimensional data. J Natl Cancer Inst. 2017;109(7):djw314. Wu X, Ye Y, Barcenas CH, Chow WH, Meng QH, Chavez-MacGregor M, Hildebrandt MAT, Zhao H, Gu X, Deng Y, Wagar E, Esteva FJ, Tripathy D, Hortobagyi GN. Personalized prognostic prediction models for breast cancer recurrence and survival incorporating multidimensional data. J Natl Cancer Inst. 2017;109(7):djw314.
10.
go back to reference Wangchinda P, Ithimakin S. Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. World J Surg Oncol. 2016;14(1):223.CrossRefPubMedPubMedCentral Wangchinda P, Ithimakin S. Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. World J Surg Oncol. 2016;14(1):223.CrossRefPubMedPubMedCentral
11.
go back to reference Ditsatham C, Somwangprasert A, Watcharachan K, Wongmaneerung P, Khorana J. Factors affecting local recurrence and distant metastases of invasive breast cancer after breast-conserving surgery in Chiang Mai University Hospital. Breast cancer (Dove Medical Press). 2016;8:47–52. Ditsatham C, Somwangprasert A, Watcharachan K, Wongmaneerung P, Khorana J. Factors affecting local recurrence and distant metastases of invasive breast cancer after breast-conserving surgery in Chiang Mai University Hospital. Breast cancer (Dove Medical Press). 2016;8:47–52.
12.
go back to reference McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ. 2006;175(1):34–41.CrossRefPubMedPubMedCentral McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ. 2006;175(1):34–41.CrossRefPubMedPubMedCentral
13.
go back to reference Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity, risk of death and recurrence in breast cancer survivors: a systematic review and meta-analysis of epidemiological studies. Acta oncologica (Stockholm, Sweden). 2015;54(5):635–54.CrossRef Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity, risk of death and recurrence in breast cancer survivors: a systematic review and meta-analysis of epidemiological studies. Acta oncologica (Stockholm, Sweden). 2015;54(5):635–54.CrossRef
14.
go back to reference Dieli-Conwright CM, Lee K, Kiwata JL. Reducing the risk of breast cancer recurrence: an evaluation of the effects and mechanisms of diet and exercise. Current Breast Cancer Rep. 2016;8(3):139–50.CrossRef Dieli-Conwright CM, Lee K, Kiwata JL. Reducing the risk of breast cancer recurrence: an evaluation of the effects and mechanisms of diet and exercise. Current Breast Cancer Rep. 2016;8(3):139–50.CrossRef
15.
go back to reference Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. The Lancet Oncology. 2010;11(10):927–33.CrossRefPubMedPubMedCentral Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. The Lancet Oncology. 2010;11(10):927–33.CrossRefPubMedPubMedCentral
16.
go back to reference Rao R, Euhus D, Mayo HG, Balch C. Axillary node interventions in breast cancer: a systematic review. JAMA. 2013;310(13):1385–94.CrossRefPubMed Rao R, Euhus D, Mayo HG, Balch C. Axillary node interventions in breast cancer: a systematic review. JAMA. 2013;310(13):1385–94.CrossRefPubMed
17.
go back to reference Bromham N, Schmidt-Hansen M, Astin M, Hasler E, Reed MW. Axillary treatment for operable primary breast cancer. The Cochrane Database Syst Rev 2017;1:Cd004561. Bromham N, Schmidt-Hansen M, Astin M, Hasler E, Reed MW. Axillary treatment for operable primary breast cancer. The Cochrane Database Syst Rev 2017;1:Cd004561.
19.
go back to reference Chen L, Chubak J, Boudreau DM, Barlow WE, Weiss NS, Li CI. Diabetes treatments and risks of adverse breast cancer outcomes among early stage breast cancer patients: a SEER-Medicare analysis. Cancer Res. 2017;77(21):6033-41. Chen L, Chubak J, Boudreau DM, Barlow WE, Weiss NS, Li CI. Diabetes treatments and risks of adverse breast cancer outcomes among early stage breast cancer patients: a SEER-Medicare analysis. Cancer Res. 2017;77(21):6033-41.
Metadata
Title
Introducing novel and comprehensive models for predicting recurrence in breast cancer using the group LASSO approach: are estimates of early and late recurrence different?
Authors
Majid Akrami
Peyman Arasteh
Tannaz Eghbali
Hadi Raeisi Shahraki
Sedigheh Tahmasebi
Vahid Zangouri
Abbas Rezaianzadeh
Abdolrasoul Talei
Publication date
01-12-2018
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2018
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-018-1489-0

Other articles of this Issue 1/2018

World Journal of Surgical Oncology 1/2018 Go to the issue